View full meeting coverage »

Eyetube Meeting Coverage:

Retina Updates Spring 2020


Editorially Independent Content, Financially Supported by


Your 25-second video preview has ended.

to continue watching, please Log In or Register:

Log in / Register

Clinical Trials Evaluating IONIS-FB-Lrx

  Channels: Retina | Posted 5/13/2020

Glenn J. Jaffe, MD, reviews data from a phase 1 study evaluating the safety of an antisense oligonucleotide designed to reduce complement factor B levels in patients with dry AMD in hopes of reducing the spread of disease. Dr. Jaffe provides an overview complement overactivity, introduces viewers to the science of antisense oligonucleotide drugs, and reviews the safety and efficacy of IONIS-FB-Lrx as seen in a phase 1 trial. He also outlines the structure of a phase 2 study evaluating the safety and efficacy of this drug.

Clinical Trials • complement factors • dry age-related macular degeneration, dry AMD • retina-meeting-recap

6 / 10 Series: Retina Updates Spring 2020

These programs are not affiliated with the official program of ARVO 2020.